Alcon Inc reported a solid top-line quarter with revenue of $2.596 billion in QQ2 2025, up 4.01% year over year and 4.97% quarter over quarter. Gross profit reached $1.389 billion, delivering a gross margin of 53.47%, while operating income was $247 million for an operating margin of 9.51%. Net income stood at $176 million, with basic and diluted EPS of $0.36 and $0.35 respectively, reflecting higher operating expenses and a modest tax impact relative to the pre-tax profit. Free cash flow was $393.96 million, supported by $490.40 million of cash provided by operations against $96.43 million of capital expenditures. The balance sheet remains strong, with cash and cash equivalents of $1.408 billion and total stockholders’ equity of $22.114 billion. However, leverage remains elevated, with total debt of $5.251 billion and net debt of $3.843 billion, which translates into a net debt to EBITDA position around 15x given the reported EBITDA of $250 million for the quarter. The combination of continued investment in R&D and SG&A, alongside a high equity base and sizable intangible assets, underpins a constructive yet cautious near-term outlook for Alcon in a competitive ophthalmology landscape.